Medicine needs departments. The body does not have them.
GLP-1 treatment, developed for metabolic control, was associated with roughly 40% fewer asthma attacks. That does not prove asthma is a metabolic disease or that one pathway explains both conditions. The mechanism remains uncertain. But the result makes one boundary visible: the categories used to organize care are not walls inside a living body.
Metabolism, immune signaling, blood vessels, and tissue reactivity can influence one another. A change aimed at one system may alter outcomes in another because physiology shares pathways, feedback loops, and chemical signals.
Specialization remains necessary. A lung complaint still deserves lung expertise. The error begins when the clinic’s map becomes the body’s reality—when each symptom is treated only where it appears and wider conditions are never examined.
The practical move is not to prescribe a metabolic drug for every airway problem. It is to widen the frame when local treatment keeps failing. Ask which shared processes may be feeding several symptoms. Test them. Keep the mechanism open until evidence closes it.
Beyond medicine, the principle remains useful: failures appearing in several places may share an upstream condition. Look beneath the visible break, then test whether the connection is real.
The body is continuous even when care is divided.